Literature DB >> 23015453

Substitution with doxorubicin for daunorubicin during induction for high risk pediatric acute lymphoblastic leukemia results in increased toxicity.

Rebecca A Gardner, Blythe Thomson, Douglas S Hawkins.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23015453     DOI： 10.1002/pbc.24325

Source DB:  PubMed          Journal:  Pediatr Blood Cancer        ISSN： 1545-5009            Impact factor:   3.167


× No keyword cloud information.
  2 in total

1.  Chemotherapy drug shortages in pediatric oncology: a consensus statement.

Authors:  Matthew Decamp; Steven Joffe; Conrad V Fernandez; Ruth R Faden; Yoram Unguru
Journal:  Pediatrics       Date:  2014-02-02       Impact factor: 7.124

2.  Mitoxantrone as a substitute for daunorubicin during induction in newly diagnosed lymphoblastic leukemia and lymphoma.

Authors:  Robert S Nickel; Frank Keller; John Bergsagel; Todd Cooper; Marla Daves; Himalee Sabnis; Glen Lew
Journal:  Pediatr Blood Cancer       Date:  2013-12-19       Impact factor: 3.167
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.